566 related articles for article (PubMed ID: 27856956)
41. CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.
Khanna A; Rane JK; Kivinummi KK; Urbanucci A; Helenius MA; Tolonen TT; Saramäki OR; Latonen L; Manni V; Pimanda JE; Maitland NJ; Westermarck J; Visakorpi T
Oncotarget; 2015 Aug; 6(23):19661-70. PubMed ID: 25965834
[TBL] [Abstract][Full Text] [Related]
42. Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer.
Chen X; Shao Y; Wei W; Zhu S; Li Y; Chen Y; Li H; Tian H; Sun G; Niu Y; Shang Z
Cell Death Dis; 2022 Nov; 13(11):927. PubMed ID: 36335093
[TBL] [Abstract][Full Text] [Related]
43. Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.
Dalal K; Ban F; Li H; Morin H; Roshan-Moniri M; Tam KJ; Shepherd A; Sharma A; Peacock J; Carlson ML; LeBlanc E; Perez C; Duong F; Ong CJ; Rennie PS; Cherkasov A
Cancer Lett; 2018 Nov; 437():35-43. PubMed ID: 30165195
[TBL] [Abstract][Full Text] [Related]
44. Hunterian Lecture. Characterisation of human prostate epithelial progenitor differentiation in response to androgens.
Heer R
Ann R Coll Surg Engl; 2011 Sep; 93(6):424-8. PubMed ID: 21929909
[TBL] [Abstract][Full Text] [Related]
45. Checkpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth.
Ta HQ; Ivey ML; Frierson HF; Conaway MR; Dziegielewski J; Larner JM; Gioeli D
Cancer Res; 2015 Dec; 75(23):5093-105. PubMed ID: 26573794
[TBL] [Abstract][Full Text] [Related]
46. Metabolism of KO143, an ABCG2 inhibitor.
Liu K; Zhu J; Huang Y; Li C; Lu J; Sachar M; Li S; Ma X
Drug Metab Pharmacokinet; 2017 Aug; 32(4):193-200. PubMed ID: 28619281
[TBL] [Abstract][Full Text] [Related]
47. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.
Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE
J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747
[TBL] [Abstract][Full Text] [Related]
48. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
[TBL] [Abstract][Full Text] [Related]
49. Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer.
Pfeiffer MJ; Smit FP; Sedelaar JP; Schalken JA
Mol Med; 2011; 17(7-8):657-64. PubMed ID: 21365123
[TBL] [Abstract][Full Text] [Related]
50. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.
Kregel S; Kiriluk KJ; Rosen AM; Cai Y; Reyes EE; Otto KB; Tom W; Paner GP; Szmulewitz RZ; Vander Griend DJ
PLoS One; 2013; 8(1):e53701. PubMed ID: 23326489
[TBL] [Abstract][Full Text] [Related]
51. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
[TBL] [Abstract][Full Text] [Related]
52. Are androgen receptor variants a substitute for the full-length receptor?
Lu J; Van der Steen T; Tindall DJ
Nat Rev Urol; 2015 Mar; 12(3):137-44. PubMed ID: 25666893
[TBL] [Abstract][Full Text] [Related]
53. Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment.
Lubik AA; Nouri M; Truong S; Ghaffari M; Adomat HH; Corey E; Cox ME; Li N; Guns ES; Yenki P; Pham S; Buttyan R
Int J Cancer; 2017 Jan; 140(2):358-369. PubMed ID: 27672740
[TBL] [Abstract][Full Text] [Related]
54. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
55. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
56. Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.
Kahn B; Collazo J; Kyprianou N
Int J Biol Sci; 2014; 10(6):588-95. PubMed ID: 24948871
[TBL] [Abstract][Full Text] [Related]
57. Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion.
Kaipainen A; Zhang A; Gil da Costa RM; Lucas J; Marck B; Matsumoto AM; Morrissey C; True LD; Mostaghel EA; Nelson PS
Prostate; 2019 Sep; 79(13):1530-1542. PubMed ID: 31376206
[TBL] [Abstract][Full Text] [Related]
58. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
[TBL] [Abstract][Full Text] [Related]
59. SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis in Prostate Cancer.
Audet-Walsh É; Vernier M; Yee T; Laflamme C; Li S; Chen Y; Giguère V
Mol Cancer Res; 2018 Sep; 16(9):1396-1405. PubMed ID: 29784665
[TBL] [Abstract][Full Text] [Related]
60. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
Axlund SD; Lambert JR; Nordeen SK
Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
